VZ
37
3
D
41
4
LEN
53
3
HUM
39
9
BLK
69
3
KMB
34
6
DG
27
-2
MDLZ
38
2
TGNA
37
-3
BRK.B
27
2
PPL
54
5
AIZ
54
7
CINF
40
5
QRVO
4
2
CL
50
2
HRB
56
2
C
54
4
IVZ
52
6
AMAT
46
6
BF.B
31
2
VZ
37
3
D
41
4
LEN
53
3
HUM
39
9
BLK
69
3
KMB
34
6
DG
27
-2
MDLZ
38
2
TGNA
37
-3
BRK.B
27
2
PPL
54
5
AIZ
54
7
CINF
40
5
QRVO
4
2
CL
50
2
HRB
56
2
C
54
4
IVZ
52
6
AMAT
46
6
BF.B
31
2
Financhill
Back

Cara Therapeutics 10K Form

Sell
40

CARA
Cara Therapeutics

Last Price:
0.30
Seasonality Move:
5.28%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2024-05-13 10Q CARA/Cara Therapeutics Quarterly
2023-11-13 10Q CARA/Cara Therapeutics Quarterly
2023-08-07 10Q CARA/Cara Therapeutics Quarterly
2023-05-15 10Q CARA/Cara Therapeutics Quarterly
2022-11-07 10Q CARA/Cara Therapeutics Quarterly
2022-08-08 10Q CARA/Cara Therapeutics Quarterly

Receive CARA News And Ratings

See the #1 stock for the next 7 days that we like better than CARA

CARA Financial Statistics

Sales & Book Value

Annual Sales: $20.97M
Cash Flow: $-12.65M
Price / Cash Flow: 0
Annual Sales: $0.21
Price / Book: 1.38

Profitability

EPS (TTM): -2.04000
Net Income (TTM): $-111.08M
Gross Margin: $14.79M
Return on Equity: -189.52%
Return on Assets: -103.2%

Cara Therapeutics Earnings Forecast

Key Cara Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 8 years for CARA is 70.56%.
  • The Selling, General & Administrative Expenses for CARA have been equal to 131.86% of Gross Profit Margin.
  • The Research & Development expenses have been 517.50% of Revenue.
  • The Interest Expense is -0.51% of Operating Income.
  • The Net Earning history of CARA is -565.21% of Total Revenues.
  • Per Share Earnings over the last 13 years have been positive in 5 years.

Cara Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: CARA
CUSIP: 140755
Website: caratherapeutics.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 4.59
Quick Ratio: 4.2

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

CARA Technical Analysis vs Fundamental Analysis

Sell
40
Cara Therapeutics (CARA) is a Sell

Is Cara Therapeutics a Buy or a Sell?

  • Cara Therapeutics stock is rated a Sell
    The current Cara Therapeutics [CARA] share price is $0.29. The Score for CARA is 40, which is 20% below its historic median score of 50, and infers higher risk than normal.